Alps Advisors Inc. Has $2.25 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Alps Advisors Inc. lessened its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 12.5% in the 3rd quarter, Holdings Channel reports. The fund owned 65,204 shares of the biotechnology company’s stock after selling 9,293 shares during the period. Alps Advisors Inc.’s holdings in Arrowhead Pharmaceuticals were worth $2,249,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtus Advisers LLC acquired a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $34,000. Salomon & Ludwin LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at $34,000. Nisa Investment Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 75.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,308 shares in the last quarter. Federated Hermes Inc. acquired a new position in Arrowhead Pharmaceuticals during the third quarter valued at $52,000. Finally, Daiwa Securities Group Inc. lifted its stake in Arrowhead Pharmaceuticals by 883.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 3,763 shares in the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Mauro Ferrari sold 7,530 shares of the stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $70.00, for a total transaction of $527,100.00. Following the transaction, the director owned 69,053 shares of the company’s stock, valued at approximately $4,833,710. This represents a 9.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Christopher Richard Anzalone sold 13,187 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $66.10, for a total value of $871,660.70. Following the completion of the sale, the chief executive officer owned 3,792,739 shares of the company’s stock, valued at approximately $250,700,047.90. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 510,836 shares of company stock worth $33,603,060 in the last 90 days. Insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $62.92 on Wednesday. The firm has a market cap of $8.81 billion, a price-to-earnings ratio of 41.12 and a beta of 1.21. The company’s fifty day moving average is $67.09 and its 200-day moving average is $44.49. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The business had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The company’s revenue for the quarter was up 10461.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.39) earnings per share. Equities analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on ARWR. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 target price (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Royal Bank Of Canada raised their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Chardan Capital upped their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Finally, Morgan Stanley lifted their target price on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $81.67.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.